HMGB1: A Promising Therapeutic Target for Prostate Cancer

High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulati...

Full description

Saved in:
Bibliographic Details
Published in:Prostate Cancer 2013-01, Vol.2013 (2013), p.15-22
Main Authors: Zheng, Guoxing, Munirathinam, Gnanasekar, Kajdacsy-Balla, André, Bosland, Maarten C., Chen, Aoshuang, Kalyanasundaram, Ramaswamy
Format: Article
Language:English
Subjects:
Analysis
Development and progression
DNA binding proteins
Health aspects
Physiological aspects
Prostate cancer
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.
ISSN:2090-3111
2090-312X
DOI:10.1155/2013/157103